Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection

Mack C. Mitchell, Asli Memisoglu, Bernard L. Silverman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: Naltrexone (Revia, Vivitrol) is recognized as having the potential for hepatotoxicity. We evaluated the safety of intramuscular extended-release naltrexone (XR-NTX) in a cohort of patients with a high prevalence of chronic hepatitis C virus (HCV) and HIV infection undergoing treatment for opioid dependence. Method: A total of 250 (88% male) opioid-dependent patients were randomized to receive monthly injections of XR-NTX 380 mg or placebo. Of the 250 subjects, 222 (88.8%) had a history of HCV; 42% were positive for HIV. Liver chemistry tests for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, gamma-glutamyl ami- notransferase (GGT), alkaline phosphatase, serum albumin, and total protein were obtained at the screening visit, at baseline, and monthly for up to 6 months. Results: In a longitudinal analysis, the frequency of elevations in AST, ALT, and GGT greater than three times the upper limit of normal (ULN) was not statistically different in patients treated with XR-NTX compared with placebo (p =.71). Most of the elevations greater than three times the ULN occurred in patients with chronic HCV infection. In patients who had a treatment-emergent elevation in AST or ALT greater than three times the ULN, the aminotransferases improved and returned toward baseline in those patients with available follow-up data. No specific symptoms were associated with any of the elevations in ALT, AST, or GGT. The frequency of elevations in AST and ALT during treatment in patients with HIV infection was not significantly different compared with that in patients without HIV infection. Conclusions: XR-NTX can be used safely in eligible patients with opioid dependence, including those with underlying mild to moderate chronic HCV and/or HIV infections.

Original languageEnglish (US)
Pages (from-to)991-997
Number of pages7
JournalJournal of Studies on Alcohol and Drugs
Volume73
Issue number6
StatePublished - Nov 2012

Fingerprint

Naltrexone
Chronic Hepatitis C
Aspartate Aminotransferases
Alanine Transaminase
HIV Infections
contagious disease
Viruses
Safety
Injections
Liver
Opioid Analgesics
Hepacivirus
Virus Diseases
Transaminases
chemistry
Bilirubin
Serum Albumin
Alkaline Phosphatase
Screening
Placebos

ASJC Scopus subject areas

  • Health(social science)
  • Psychiatry and Mental health
  • Toxicology

Cite this

Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. / Mitchell, Mack C.; Memisoglu, Asli; Silverman, Bernard L.

In: Journal of Studies on Alcohol and Drugs, Vol. 73, No. 6, 11.2012, p. 991-997.

Research output: Contribution to journalArticle

@article{7d9bf3cf07834ea8a084f9bb9c5dc5d1,
title = "Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection",
abstract = "Objective: Naltrexone (Revia, Vivitrol) is recognized as having the potential for hepatotoxicity. We evaluated the safety of intramuscular extended-release naltrexone (XR-NTX) in a cohort of patients with a high prevalence of chronic hepatitis C virus (HCV) and HIV infection undergoing treatment for opioid dependence. Method: A total of 250 (88{\%} male) opioid-dependent patients were randomized to receive monthly injections of XR-NTX 380 mg or placebo. Of the 250 subjects, 222 (88.8{\%}) had a history of HCV; 42{\%} were positive for HIV. Liver chemistry tests for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, gamma-glutamyl ami- notransferase (GGT), alkaline phosphatase, serum albumin, and total protein were obtained at the screening visit, at baseline, and monthly for up to 6 months. Results: In a longitudinal analysis, the frequency of elevations in AST, ALT, and GGT greater than three times the upper limit of normal (ULN) was not statistically different in patients treated with XR-NTX compared with placebo (p =.71). Most of the elevations greater than three times the ULN occurred in patients with chronic HCV infection. In patients who had a treatment-emergent elevation in AST or ALT greater than three times the ULN, the aminotransferases improved and returned toward baseline in those patients with available follow-up data. No specific symptoms were associated with any of the elevations in ALT, AST, or GGT. The frequency of elevations in AST and ALT during treatment in patients with HIV infection was not significantly different compared with that in patients without HIV infection. Conclusions: XR-NTX can be used safely in eligible patients with opioid dependence, including those with underlying mild to moderate chronic HCV and/or HIV infections.",
author = "Mitchell, {Mack C.} and Asli Memisoglu and Silverman, {Bernard L.}",
year = "2012",
month = "11",
language = "English (US)",
volume = "73",
pages = "991--997",
journal = "Journal of Studies on Alcohol and Drugs",
issn = "1937-1888",
publisher = "Alcohol Research Documentation, Inc.",
number = "6",

}

TY - JOUR

T1 - Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection

AU - Mitchell, Mack C.

AU - Memisoglu, Asli

AU - Silverman, Bernard L.

PY - 2012/11

Y1 - 2012/11

N2 - Objective: Naltrexone (Revia, Vivitrol) is recognized as having the potential for hepatotoxicity. We evaluated the safety of intramuscular extended-release naltrexone (XR-NTX) in a cohort of patients with a high prevalence of chronic hepatitis C virus (HCV) and HIV infection undergoing treatment for opioid dependence. Method: A total of 250 (88% male) opioid-dependent patients were randomized to receive monthly injections of XR-NTX 380 mg or placebo. Of the 250 subjects, 222 (88.8%) had a history of HCV; 42% were positive for HIV. Liver chemistry tests for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, gamma-glutamyl ami- notransferase (GGT), alkaline phosphatase, serum albumin, and total protein were obtained at the screening visit, at baseline, and monthly for up to 6 months. Results: In a longitudinal analysis, the frequency of elevations in AST, ALT, and GGT greater than three times the upper limit of normal (ULN) was not statistically different in patients treated with XR-NTX compared with placebo (p =.71). Most of the elevations greater than three times the ULN occurred in patients with chronic HCV infection. In patients who had a treatment-emergent elevation in AST or ALT greater than three times the ULN, the aminotransferases improved and returned toward baseline in those patients with available follow-up data. No specific symptoms were associated with any of the elevations in ALT, AST, or GGT. The frequency of elevations in AST and ALT during treatment in patients with HIV infection was not significantly different compared with that in patients without HIV infection. Conclusions: XR-NTX can be used safely in eligible patients with opioid dependence, including those with underlying mild to moderate chronic HCV and/or HIV infections.

AB - Objective: Naltrexone (Revia, Vivitrol) is recognized as having the potential for hepatotoxicity. We evaluated the safety of intramuscular extended-release naltrexone (XR-NTX) in a cohort of patients with a high prevalence of chronic hepatitis C virus (HCV) and HIV infection undergoing treatment for opioid dependence. Method: A total of 250 (88% male) opioid-dependent patients were randomized to receive monthly injections of XR-NTX 380 mg or placebo. Of the 250 subjects, 222 (88.8%) had a history of HCV; 42% were positive for HIV. Liver chemistry tests for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, gamma-glutamyl ami- notransferase (GGT), alkaline phosphatase, serum albumin, and total protein were obtained at the screening visit, at baseline, and monthly for up to 6 months. Results: In a longitudinal analysis, the frequency of elevations in AST, ALT, and GGT greater than three times the upper limit of normal (ULN) was not statistically different in patients treated with XR-NTX compared with placebo (p =.71). Most of the elevations greater than three times the ULN occurred in patients with chronic HCV infection. In patients who had a treatment-emergent elevation in AST or ALT greater than three times the ULN, the aminotransferases improved and returned toward baseline in those patients with available follow-up data. No specific symptoms were associated with any of the elevations in ALT, AST, or GGT. The frequency of elevations in AST and ALT during treatment in patients with HIV infection was not significantly different compared with that in patients without HIV infection. Conclusions: XR-NTX can be used safely in eligible patients with opioid dependence, including those with underlying mild to moderate chronic HCV and/or HIV infections.

UR - http://www.scopus.com/inward/record.url?scp=84867594521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867594521&partnerID=8YFLogxK

M3 - Article

C2 - 23036218

AN - SCOPUS:84867594521

VL - 73

SP - 991

EP - 997

JO - Journal of Studies on Alcohol and Drugs

JF - Journal of Studies on Alcohol and Drugs

SN - 1937-1888

IS - 6

ER -